Long-term efficacy of etanercept in hidradenitis suppurativa: results from an open-label phase II prospective trial.
OBJECTIVE
To evaluate the long-term efficacy of etanercept for the management of hidradenitis suppurativa.


METHODS
Analysis was based on the long-term follow-up (weeks 24-144) of 10 patients enrolled in a prospective open-label phase II study; etanercept was initially administered subcutaneously 50 mg once weekly for 12 weeks in 10 patients. Disease recurrence and the need to restart etanercept were recorded.


RESULTS
Three patients did not report any disease recurrence. A second course of treatment with etanercept was needed in seven patients. Favourable responses were found in five; two patients failed treatment.


CONCLUSIONS
The first treatment course achieved long-term disease remission in almost one-third of patients. The remaining needed a second treatment course but even in that case, their disease severity at restart was significantly lower compared with baseline.
Pelekanou
Aimilia
A
Kanni
Theodora
T
Savva
Athina
A
Mouktaroudi
Maria
M
Raftogiannis
Maria
M
Kotsaki
Antigone
A
Giamarellos-Bourboulis
Evangelos J
EJ
D000293:Adolescent; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000068800:Etanercept; D005260:Female; D005500:Follow-Up Studies; D017497:Hidradenitis Suppurativa / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D012008:Recurrence; D012074:Remission Induction; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept